113 related articles for article (PubMed ID: 9010616)
1. Molecular modelling study of the binding of inhibitors of aromatase to the cytochrome P-450 heme.
Ahmed S; Davis PJ; Owen CP
Drug Des Discov; 1996 Oct; 14(2):91-102. PubMed ID: 9010616
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biochemical evaluation of novel inhibitors of aromatase (AR) using an enhanced representation of the active site of AR derived from the consideration of the reaction mechanism.
Ahmed S; Amanuel Y
Biochem Biophys Res Commun; 2000 Jan; 267(1):356-61. PubMed ID: 10623624
[TBL] [Abstract][Full Text] [Related]
3. Molecular modelling study of pyrrolidine-2,5-dione based aromatase inhibitors and other known inhibitors.
Ahmed S
Drug Des Discov; 1996 Mar; 14(1):77-89. PubMed ID: 8854046
[TBL] [Abstract][Full Text] [Related]
4. Novel oxazolidinone based compounds as inhibitors of aromatase and the use of the substrate-heme complex approach in the rationalisation of these compounds.
Ahmed S; Adat S; Murrells A; Owen CP
Biochem Biophys Res Commun; 2002 Jun; 294(2):380-3. PubMed ID: 12051723
[TBL] [Abstract][Full Text] [Related]
5. Pharmacology of aminoglutethimide: structure/activity relationships and receptor interactions.
Nicholls PJ; Daly MJ; Smith HJ
Breast Cancer Res Treat; 1986; 7 Suppl():S55-67. PubMed ID: 3755630
[TBL] [Abstract][Full Text] [Related]
6. Molecular Action and Clinical Relevance of Aromatase Inhibitors.
Murphy MJ
Oncologist; 1998; 3(2):129-130. PubMed ID: 10388095
[TBL] [Abstract][Full Text] [Related]
7. Aromatase inhibitors: synthesis, biological activity, and binding mode of azole-type compounds.
Furet P; Batzl C; Bhatnagar A; Francotte E; Rihs G; Lang M
J Med Chem; 1993 May; 36(10):1393-400. PubMed ID: 8496907
[TBL] [Abstract][Full Text] [Related]
8. Binding characteristics of aromatase inhibitors and phytoestrogens to human aromatase.
Chen S; Kao YC; Laughton CA
J Steroid Biochem Mol Biol; 1997 Apr; 61(3-6):107-15. PubMed ID: 9365179
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and structure-activity relationships of 6-substituted androst-4-ene analogs as aromatase inhibitors.
Numazawa M; Kamiyama T; Tachibana M; Oshibe M
J Med Chem; 1996 May; 39(11):2245-52. PubMed ID: 8667367
[TBL] [Abstract][Full Text] [Related]
10. Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme.
Gobbi S; Cavalli A; Rampa A; Belluti F; Piazzi L; Paluszcak A; Hartmann RW; Recanatini M; Bisi A
J Med Chem; 2006 Jul; 49(15):4777-80. PubMed ID: 16854084
[TBL] [Abstract][Full Text] [Related]
11. Review of the molecular modelling studies of the cytochrome P-450 estrogen synthetase enzyme, aromatase.
Ahmed S
Drug Des Discov; 1998 Oct; 15(4):239-52. PubMed ID: 10546069
[TBL] [Abstract][Full Text] [Related]
12. Conformational analysis of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione (rogletimide) and discovery of potent 5-alkyl derivatives.
McCague R; Rowlands MG
J Med Chem; 1992 Oct; 35(20):3699-704. PubMed ID: 1433182
[TBL] [Abstract][Full Text] [Related]
13. 6 beta-Propynyl-substituted steroids: mechanism-based enzyme-activated irreversible inhibitors of aromatase.
Akkani A; Paterlini G; Gleason WB; Ojala WH; Abul-Hajj YJ
J Med Chem; 1997 Sep; 40(20):3263-70. PubMed ID: 9379446
[TBL] [Abstract][Full Text] [Related]
14. Molecular docking and QSAR study on steroidal compounds as aromatase inhibitors.
Dai Y; Wang Q; Zhang X; Jia S; Zheng H; Feng D; Yu P
Eur J Med Chem; 2010 Dec; 45(12):5612-20. PubMed ID: 20926163
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and characterization of azole isoflavone inhibitors of aromatase.
Hackett JC; Kim YW; Su B; Brueggemeier RW
Bioorg Med Chem; 2005 Jun; 13(12):4063-70. PubMed ID: 15911319
[TBL] [Abstract][Full Text] [Related]
16. Three-dimensional model of cytochrome P450 human aromatase.
Loge C; Le Borgne M; Marchand P; Robert JM; Le Baut G; Palzer M; Hartmann RW
J Enzyme Inhib Med Chem; 2005 Dec; 20(6):581-5. PubMed ID: 16408794
[TBL] [Abstract][Full Text] [Related]
17. Probing the binding pocket of the active site of aromatase with 2-phenylaliphatic androsta-1,4-diene-3,17-dione steroids.
Takahashi M; Yamashita K; Numazawa M
Steroids; 2010 Apr; 75(4-5):330-7. PubMed ID: 20096721
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationships of new A,D-ring modified steroids as aromatase inhibitors: design, synthesis, and biological activity evaluation.
Cepa MM; Tavares da Silva EJ; Correia-da-Silva G; Roleira FM; Teixeira NA
J Med Chem; 2005 Oct; 48(20):6379-85. PubMed ID: 16190763
[TBL] [Abstract][Full Text] [Related]
19. Time-dependent inactivation of aromatase by 6-alkylandrosta-1,4-diene-3,17-diones. Effects of length and configuration of 6-alkyl group.
Numazawa M; Oshibe M; Yamaguchi S; Tachibana M
J Med Chem; 1996 Mar; 39(5):1033-8. PubMed ID: 8676338
[TBL] [Abstract][Full Text] [Related]
20. Molecular basis for the interaction of four different classes of substrates and inhibitors with human aromatase.
Hong Y; Cho M; Yuan YC; Chen S
Biochem Pharmacol; 2008 Mar; 75(5):1161-9. PubMed ID: 18184606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
